Submitted for Publication: October 31, 2011; final revision received February 21, 2012; accepted February 27, 2012.
Published Online: May 14, 2012. doi:10.1001/archophthalmol.2012.827. Corrected on July 12, 2012.
Financial Disclosure: Drs Medeiros, Lisboa, Girkin, Liebmann, and Zangwill received research support from Carl Zeiss Meditec, Inc, and Drs Medeiros, Weinreb, Liebmann, and Zangwill received research support from Heidelberg Engineering. Dr Weinreb is a consultant to Carl Zeiss Meditec, Inc.
Funding/Support: This study was supported in part by grants EY021818 (Dr Medeiros), EY13959 (Dr Girkin), EY11008 (Dr Zangwill), and EY14267 (Dr Zangwill) from the National Eye Institute, National Institutes of Health; an unrestricted grant from Research to Prevent Blindness to the Department of Ophthalmology at University of California, San Diego; and the Eyesight Foundation. Grants were received for participants' glaucoma medications from Alcon Laboratories; Allergan, Inc; Pfizer, Inc; Merck & Co; and Santen Pharmaceutical.
Role of the Sponsor: The grant providers had no role in the design and conduct of the study; in the collection, analysis, and interpretation of the data; or in the preparation, review, or approval of the manuscript.